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Abstract
This study aims to examine whether or not cancer stem cells exist in malignant peripheral nerve sheath tumors (MPNST).
Cells of established lines, primary cultures and freshly dissected tumors were cultured in serum free conditions
supplemented with epidermal and fibroblast growth factors. From one established human MPNST cell line, S462, cells
meeting the criteria for cancer stem cells were isolated. Clonal spheres were obtained, which could be passaged multiple
times. Enrichment of stem cell-like cells in these spheres was also supported by increased expression of stem cell markers
such as CD133, Oct4, Nestin and NGFR, and decreased expression of mature cell markers such as CD90 and NCAM.
Furthermore, cells of these clonal S462 spheres differentiated into Schwann cells, smooth muscle/fibroblast and neurons-
like cells under specific differentiation-inducing cultural conditions. Finally, subcutaneous injection of the spheres into
immunodeficient nude mice led to tumor formation at a higher rate compared to the parental adherent cells (66% versus
10% at 2.5610
5). These results provide evidence for the existence of cancer stem cell-like cells in malignant peripheral nerve
sheath tumors.
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Introduction
Malignant peripheral nerve sheath tumors (MPNSTs) are soft
tissue sarcomas arising from peripheral nerves and have high rates
of local recurrence and hematogenous metastasis [1]. They account
for 10% of all soft tissue sarcomas. Half of these malignancies occur
in patients with neurofibromatosis type 1, a tumor suppressor gene
syndrome with an incidence of approximately 1 in 3000. MPNST,
especially those associated with neurofibromatosis type 1, are one of
the most aggressive malignancies in humans with an extremely poor
prognosis [2].
Results of recent studies suggest that many malignant tumors
contain cells with properties of stem cells including self-renewal,
clonality, multipotency, and high rates of tumor formation in
immunodeficient mice [3,4]. Like embryonic stem cells, cancer
stem cells are postulated to be drug resistant [5,6]. In our recent
clinical trial using imatinib mesylate, a tyrosine kinase receptor
inhibitor, several patients with MPNST showed initially promising
responses as their tumors shrunk to very small cores. However,
relapse occurred in all cases and the recurring tumors did not
respond to the original therapy any more (unpublished observa-
tions). Possibly, a small portion of stem cell-like cells escaped the
therapy and led to relapse.
While cancer stem cells have been reported and extensively
studied in a number of solid tumors [7–9], they have not yet been
identified inMPNSTs.Inthepresentstudy,wetestedthehypothesis
that MPNSTs also contain stem cell-like cells, which can be
enriched in vitro. The stem cell-like cells from one established human
MPNST cell line, S462, were further characterized in vitro, in vivo
and molecularly.
Materials and Methods
Patients and tumors
The diagnosis of neurofibromatosis type 1 was made according
to the National Institute of Health diagnostic criteria [10].
MPNST tumors (n=12), plexiform (n=3) and cutaneous
neurofibromas (n=3) were obtained mostly from the Surgical
and Maxillofacial Surgical Departments of the University Medical
Center Hamburg-Eppendorf and some from the Neurofibroma-
tosis Clinic, Munich. The obtention of tumors was approved by
the local review board (Hamburg A ¨rztkammer, OB-011/07) and
all patients gave written consent. Immediately after surgical
removal, the specimens were placed in Hanks buffered saline
(Gibco, Paisley, UK). One part of each specimen was used to
confirm the pathological diagnosis of the tumor (Institute of
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other part was snap frozen in liquid nitrogen and stored at 280uC.
The remaining tissue was used for cell culture.
Cell culture
Cells of established MPNST cell lines S462 and S1507-2 were
cultured under standard conditions with serum [11]. Dissociation
and culturing cells from freshly resected MPNSTs were as
described previously [11].
Enrichment of stem cell-like cells
Cells of established lines, primary cultures and freshly dissociated
tumors were cultured under stem cell conditions in stem cell
medium (SCM) consisting of Neurobasal Medium (Invitrogen,
Karlsruhe, Germany) with human recombinant epidermal growth
factor (EGF, 20 ng/ml, R&D systems, Minneapolis, MN), basic
fibroblast growth factor (bFGF, 20 ng, Prepotech, Rocky Hill, NJ),
heparin (32 IE/ml, Rathiopharm, Ulm, Germany) and supple-
mented with 1% N2 and 1% B27 (both from Invitrogen). Densities
of the plated cells ranged from single to 500 cells per well. To
passage spheres, spheres were collected by gentle centrifugation at
800 g for 5 min, and mechanically dissociated by pipetting up and
down using a 1 ml pipette. Thereafter, the cell suspension was
filtered through a 30 mm mesh filter to remove remaining
aggregates. Single cells were then plated at various densities
in SCM.
Cell proliferation assays
Cell proliferation was assessed using the bromodeoxyuridine
incorporation assay (Roche, Mannheim, Germany) following the
manufacturer’s instructions. Absorbance was read on a spectro-
photometer at a wavelength of 405 nm.
Clonal sphere formation
Cells were plated at low density in 96 well-plates. Wells
containing single cells were marked while those containing more
than one cell per well were excluded from the analysis. After two
(or three) weeks, wells containing spheres were counted. Frequency
of sphere formation was calculated as the proportion of wells
containing spheres against wells containing single cells.
Real-time PCR
RNA was prepared from spheres and adherent cells using
NucleoSpin RNA XS columns (Macherey Nagel, Du ¨ren, Ger-
many). For cDNA synthesis we used random hexamer primers
(Fermentas, St.Leon-Rot, Germany) and Revert Aid Reverse
Transcriptase (Fermentas). For gene expression analyses validated
TaqMan Gene Expression Assays (Applied Biosystems, Darm-
stadt, Germany) were used. For CD133 discrimination we used
TaqMan Gene Expression Assays binding in Exon 2/3 and Exon
4/5 of CD133. Relative amounts of target RNA were normalised
to ribosomal protein L13a (RPL13a) as internal control and
relative quantitative values were calculated according to the DDCt
method.
Flow cytometry
For detection of surface markers CD133, CD34, nerve growth
factor receptor (NGFR, CD271), neural cell adhesion molecule
(NCAM, CD56) and CD90, cells were suspended in 30 mlo f
antibody diluent buffer (Beckman Coulter, Krefeld, Germany) and
10 ml anti-CD133/2-PE (Miltenyi Biotec, Bergisch Gladbach,
Germany), 11 ml CD271-FITC (R&D), 5 ml CD34-PE, 5 ml
CD56-PC5 or 5 ml CD90-PC7 (Beckmann Coulter) were added
(optimal antibody concentrations were determined by several
dilution experiments). As negative controls, cells were incubated in
the same buffer supplemented with 10 ml IgG1-PE, 10 ml IgG1-
FITC, 5 ml IgG1-PC5, 10 ml IgG1-PC7 (Beckmann Coulter) for
30 min at 4uC. For detection of the intracellular antigen Nestin
(R&D), cells were fixed and permeabilized with AB reagent
following the manufacture’s instructions (R&D) and 10 ml Nestin-
PE (R&D) or 10 ml IgG1-PE were added for 30 min at 4uC.
After washing with phosphate buffer saline, cells were analyzed
within 1 h by flow cytometry either on a FC 500 flow cytometer
using CXP software (Beckman Coulter) or on a PAS Particle
Analyzing System (Partec, Mu ¨nster, Germany).
Magnetic cell sorting
Cells suspended in phosphate buffer saline containing 0.5%
Bovine Serum Albumin and 2 mM EDTA were labelled
magnetically with anti-CD133/2, CD34 and CD271 microbeads
using the Miltenyi Biotec CD133/2, CD34, CD271 microbead
kits following the manufacture’s instructions. Magnetic separation
was carried out with MACS separation columns (Miltenyi Biotec).
Positive and negative fractions were eluted three times to increase
the purity of the samples. Aliquots of positive and negative sorted
cells were evaluated for purity by flow cytometry with a FC 500
flow cytometer using CXP software (Beckman Coulter).
Cell differentiation assays
Dissociated spheres or parental adherent cells were plated into
wells coated with poly-lysine and laminin, and grown in
DMEM:F-12 (3:1) containing 10% fetal bovine serum. For glia
differentiation, 5 ng/ml recombinant human neuregulin-ß1 (kind-
ly provided by Dr. S. Carroll, Division of Neuropathology,
Department of Pathology, University of Alabama at Birmingham,
Birmingham, Alabama) and 2 mM forskolin (Sigma, Munich,
Germany) were added for at least 2 weeks [12]. For smooth muscle
fibroblast (SM/Fb) differentiation, 40 ng/ml bFGF (Prepotech)
was added for 5 days, and then 1 ng/ml transforming growth
factor- ß1 (Sigma) was added for 7 days [12]. For neurons,
neurobasal medium was supplemented with 1 mM retinoic acid
(Sigma), 10 mg/ml cyclic AMP (Sigma), 1% B27, and 2 mM
glutamine [7] for 1 week or longer. For all conditions, medium was
changed every three days.
Immunofluorescence staining
Cells grown on chamber slides were fixed with 4% parafor-
maldehyde and stained with the following antibodies: rabbit anti-
human S100 (1:500, DAKO, Hamburg, Germany), rabbit anti-
smooth muscle actin (1:100, Santa Cruz, Heidelberg, Germany),
mouse anti-human microtubule associated protein (MAP)-2
(Millipore, Schwalbach, Germany), mouse anti-human NGFR
(1:100, Millipore), mouse anti-human neurofilament (1:400,
Millipore) and mouse anti-human Nestin (1:200, Millipore). For
double labelling S100 with either neurofilament or NGFR, the
same procedure was used for the second primary antibodies and a
second antibody raised in another species and labelled with
another dye was used. Appropriate isotype controls and the
omission of primary and secondary antibodies were used to rule
out possible non-specific immunolabelling. Nuclei were labelled
with 49,6-diamidino-2-phenylindole (Invitrogen).
Tumorigenicity assay in nude mice
A t h y m i cn u d em i c e( C h a r l e sR i v e r )w e r eb r i e f l ya n a e s t h e -
tised with a mixture of CO2/02 a n dd i s s o c i a t e ds p h e r e so r
adherent cells suspended in 50% Matrigel (R&D) were injected
MPNST Cancer Stem Cells
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twice a week. All animal experiments were approved by the
local authority (Beho ¨rde fu ¨r Wissenschaft und Gesundheit,
Hamburg, 68/06).
Tumors grown in mice were removed, fixed in 7% formalin and
embedded in paraffin. Sections were stained with hematoxylin.
For immunohistochemistry we used rabbit anti-human S100
(1:500) and rabbit anti-human Ki67 (1:50, Neomarkers, Asbach,
Germany) antibodies. For antibody detection, the Envision Kit
dual system peroxidase (Dako) was used. Colour reactions were
developed with VectorRed (Vector Laboratories, Burlingame, CA)
and the nuclei were counterstained with hematoxylin.
Data analysis
The comparison of frequency of sphere formation between
different passages and the increase in the number of cells capable
of forming tumor spheres with passaging was tested by a non-
parametric ANOVA; if significant, post-hoc comparisons using
Dunn’s test were performed. The increase in the number of
proliferative cells over time was analysed using a non-parametric
repeated measurements ANOVA; if significant, post-hoc compar-
ison using Tukeys’s test was performed. The same test was
performed to compare an increase in proliferation of CD133
positive and negative spheres over time. Differences in the relative
amount of cDNA analysed by RT-PCR, and changes in the
percentage of positive cells in parental adherent cells and spheres
analysed by flow cytometry, were tested using the non-parametric
Mann-Whitney U-test. Differences in the frequency of tumor
formation between mice injected with adherent cells and spheres
respectively, were calculated by the Chi-square test. All averaged
values are represented as the mean6 standard error of the mean
(SEM). Values were considered significant when p,0.05.
Results
Sphere formation from MPNST cells
To examine whether ornotMPNSTscontainstem-likecells,cells
from 2 established lines and 12 dissected tumors were cultured in
serum-free medium containing EGF and FGF. Spheres or sphere-
like aggregates were obtained from the two cell lines and 10 out of
the 12 dissected fresh tumors. Spheres formed at low density, as low
as one cell per well, and propagated for at least 20 passages from the
established MPNST cell line S462. Spheres or sphere-like
aggregates were also obtained from another established MPNST
line (S1507-2) and from primary MPNST cells and freshly dissected
MPNSTs; however, they survived only for 2 to 12 passages, and
could not be obtained at cell densities below 100 cells per well.
Similarly, spheres or sphere-like aggregates were also obtained from
primary cultures derived from plexiform neurofibromas and
cutaneous neurofibromas, but could be not be passaged more than
twice. Further experiments thus focused on spheres of S462.
In vitro characterization of MPNST S462 spheres
Parental MPNST S462 cells of passage 35, which under
standard medium conditions with serum grow adherently, formed
floating spheres after 2 days under stem cell conditions (Fig. 1A,B;
adherent S462 cells refer to the parental S462 cell line).
Proliferation of cells in the spheres demonstrated that these were
not just aggregates (Fig. 2A). When these primary spheres were
dissociated and the cells plated at extremely low density in wells of
a 96-well plate, secondary spheres were obtained in 16.7%62.4 of
wells containing single cells. The frequency of sphere formation
from single cells increased when the spheres were passaged further
(Fig. 2B). Clonal spheres were also obtained from adherent S462
cells of the very early passage 2, with a higher frequency of
primary sphere formation 31.86%62.50, almost twice as high as
with adherent S462 cells of passage 35. To date, MPNST S462
spheres have been passaged under clonal conditions over 20 times.
Up-regulation of stem cell markers and down regulation
of mature cell markers in S462 spheres
Real-Time PCR revealed up-regulation of stem cell markers
Nestin, NGFR, Oct4, Notch4, SOX2, CD133 and SOX9 in S462
spheres of passages between 13 and 16, in comparison to S462
adherent cells kept under the SCM culturing conditions for 14–
16 hours (Fig. 3A, left). In contrast, EGF receptor (EGFR) and
NCAM, a marker of immature Schwann cells, were expressed at
lower levels in S462 spheres than in their parental adherent cells
(Fig. 3A, right).
Flow cytometry revealed increased expression of neural crest
markers NGFR, CD133 and Nestin in the spheres compared to
parental adherent S462 cells (Fig. 3B). The proportion of cells
expressing CD34 was also increased in the spheres to about 50%. In
addition, approximately 60% of the NGFR positive population co-
expressed-CD133 in adherent S462 and in the spheres
(66.84610.82% adherent versus 60.81612.21% spheres, not
Figure 1. Comparison of MPNST adherent and sphere cultures. (A) Parental S462 cells under standard culture conditions with serum grow
adherently (passage 35). (B) Floating secondary sphere after two weeks under stem cell conditions without serum. The sphere was derived from a
single cell and thus was clonal. Bars=20 mm.
doi:10.1371/journal.pone.0021099.g001
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less frequently in S462 spheres than in adherent cells (Fig. 3B).
Higher frequency of S462 sphere formation and
proliferation in CD133+ cells
Using magnetic bead-based sorting, we enriched CD133
positive and negative cells from the serum-cultured adherent
S462 cells (passage 35) to 90 and 80%, respectively, and cultured
them separately in SCM at low cell density. More spheres formed
in the CD133+ population when compared to the CD1332
population (35.21% versus 18.35%). In addition, cells in CD133+
spheres proliferated more rapidly than those in the CD1332
spheres (absorbance at 405 nm of 0.760.047 versus 0.3960.0312,
p,0.001).
S462 spheres are capable of lineage differentiation
To assess the potential for multilineage-differentiation, clonally
derived spheres and adherent S462 cells from passage 35 were
both cultured in medium containing serum, which induces
differentiation. After two to three weeks, expression of S100 was
observed in a small number of cells from S462 clonal spheres,
indicating lineage differentiation to Schwann cell-like cells. In
contrast, expression of this marker was not observed in the
adherent S462 cells (data not shown). More than 50% of cells from
the clonal spheres expressed Nestin when cultured in serum-
containing medium, compared to none of the adherent S462 cells
(data not shown).
Adding neuregulin and forskolin induced specific differentia-
tion to S100+ Schwann cells in nearly all cells of clonal S462
Figure 2. Proliferation and self-renewal of MPNST spheres. Bromodeoxyuridine incorporation assay revealed proliferation of S462 cells in the
clonal spheres (secondary spheres). The increase in cell absorbance was significant for 8, 10, and 15 days in SCM versus 3 days (p,0.01 **). Changes in
the frequency of sphere formation in wells containing single cells originally from adherent S462, then from dissociated spheres plated as single cells
and passaged consecutively. The increase in frequency of sphere formation with increasing passage was significant (passage 1 (primary spheres)
versus passages 10 (10
th spheres) and 12 (12
th spheres), P,0.01 **, passage 2 (secondary spheres) versus passages 10 (10
th spheres) and 12
th
spheres), P,0.05*).
doi:10.1371/journal.pone.0021099.g002
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really positive for S100 and showed slight different morphology
(Fig. 5A). The bi-polar morphology of the S100+ Schwann cells
differentiated from clonal spheres (Fig. 5A, D) was similar to that
of Schwann cells derived from a plexiform neurofibroma (Fig. 5A
insert). These differentiated cells from clonal spheres also
expressed the Schwann cell markers neurofilament and NGFR
(Fig. 5A), adherent cells expressed neurofilament but very rarely
NGFR (data not shown).
Similarly, exposure to bFGF and transforming growth factor-ß1
induced specific differentiation to SM/Fb-like cells in a large
portion of cells from clonal S462 spheres while only a few S462
adherent cells showed smooth muscle actin expression and
fibroblastoid morphology (Fig. 5B, D).
Finally, cyclic AMP and retinoic acid induced neurogenic
lineage differentiation in cells of clonal spheres, as they expressed
MAP-2 and exhibited neuron-specific morphology such as large
cell bodies and neurites (Fig. 5C, D). In contrast, while adherent
cells expressed MAP-2 under the same cultural conditions
(Fig. 5C), these cells did not exhibit neuron-like morphology.
In vivo characterization of S462 sphere cells
Subcutaneous injection of 2.5610
5 cells of clonal S462 spheres
(n=9) led to visible solid tumor formation 1 to 3 months after
Figure 3. Comparative expression of stem cell markers and mature cell markers in adherent and S462 spheres. (A) Real-Time PCR.
Expression of each marker in the spheres was normalized against expression of the same marker in the adherent S462 cells. Spheres at passages
between 13 and 16. * p,0.05; adherent versus sphere transcript expression (Nestin, NGFR, Oct4, Sox2, CD133, Sox9, EGFR and NCAM). (B) Flow
cytometry. Changes in the percentage of cells expressing mature and stem cell progenitor markers in adherent cells and in spheres (passages 8 and
13), CD133 and NCAM adherent versus spheres p,0.05 *, CD34 and CD90 adherent versus spheres p,0.01 **, NGFR and Nestin adherent versus
spheres p,0.01 ***. EGFR, epidermal growth factor receptor; NGFR, nerve growth factor receptor; NCAM, cell adhesion molecule.
doi:10.1371/journal.pone.0021099.g003
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only formed in 10% of nude mice (n=10) when the same number
of adherent S462 cells was injected, this tumor needed over three
months to form (Fig. 6A). Histologically, tumors from both
adherent cells and spheres exhibited typical characteristics of
MPNST: spindle shaped, highly proliferative as shown with high
Figure 4. Co-expression of NGFR and CD133 in adherent and S462 spheres. Side and forward scatter analysis of adherent cells (left column)
and spheres (at passage 8, right column) showed different types of cells. Live cells were gated in R1 (upper panels), and gatings for NGFR (R2) positive
cells (middle panels) are shown in orange. NGFR-positive cells (represented in orange) within the CD133-positive cells show co-expression of CD133/
NGFR (lower panels). NGFR cells co-expressing CD133 are infrequent in the adherent cell population and increased in spheres. Isotype controls for all
the antigens were used to set up the quadrants for negative populations. NGFR, nerve growth factor receptor.
doi:10.1371/journal.pone.0021099.g004
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(Figure 6B).
When 2.5610
5 cells from CD133+ spheres (n=9) and CD1332
spheres (n=5) were injected into nude mice subcutaneously, only
CD133+ cells led to visible tumor formation in 55% of the mice,
between two weeks and 1 month after injection (Fig. 6A). When
5.6610
4 cells from CD133+ spheres (n=3) were injected, tumors
formed in 66% of the mice and took about one month to develop.
In contrast, 2.5610
5 cells from CD1332 spheres did not lead to
any visible tumor formation; and higher numbers of cells (5610
6,
n=7) led to visible tumors in only 14% of mice and approximately
2 months after injection.
When the tumors from mice were freshly dissociated and plated
as single cells in stem cell culture conditions, round spheres
appeared within two days (Fig. 6C). These spheres could be grown
clonally over consecutive passages. The frequency of sphere
formation of cells from tumors grown in mice was approximately
32%, higher than that of adherent S462 cells at passage 35 (which
was approximately 17%), while comparable to that of adherent
S462 cells at passage 2, which was around 31%.
Discussion
In this study, we applied culture conditions optimised for neural
stem cells, for the enrichment of cancer stem-like cells from
MPNSTs. We succeeded in obtaining and enriching such cells from
one established MPNST cell line, S462, and thus demonstrated that
cancer stem-like cells exist in MPNST. Spheres could be obtained
Figure 5. Multi-lineage differentiation of cells of clonal S462 spheres. Adherentcells(leftcolumn)anddissociatedspherecells(rightcolumns)
were cultured with growth factors inducing differentiation into cells resembling (A) Schwann cells, (B) SM/Fb and (C) neurons, which are positively
stained for S100/NGFR/neurofilament (Schwann cells), SMA (SM/Fb), and MAP-2 (neurons), respectively. Insert in A illustrates S100+ Schwann cells
derivedfromaplexiformneurofibromaculture.(D)phasecontrastmicrographsfromdifferentiatedcellsunder3 cultureconditionstogenerateSchwann
cell, SM/Fb and neuron-like cells. Differentiated cells are indicated by arrows and non-differentiated cells by arrowheads. Bars=20 mm. NGFR, nerve
growth factor; SMA, smooth muscle actin; MAP-2, microtubule associated protein-2; PNF, plexiform neurofibroma; LC, like-cells.
doi:10.1371/journal.pone.0021099.g005
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proliferating spheres and not aggregates of cells. Spheres were also
obtained from primary S462 at passage 2, with an even higher
frequency. It is thus unlikely that the stem-like cells we obtained,
enriched and studied are an artefact of long-term culture.
We could not obtain clonal spheres that could be passaged from
a second MPNST cell line, several primary MPNST cultures,
freshly dissected tumors or plexiform and cutaneous neurofibro-
mas [12]. MPNST tumors are clinically, genetically and
histopathologically very heterogeneous [1]. It is possible that only
the S462 line, which was derived from a very aggressive and
recurrent tumor, contains an adequate proportion of stem cell-like
cells that are immature enough to enable formation of clonal
spheres under the selected conditions. Spheres from some other
MPNSTs could be passaged at higher densities up to 12 times,
indicating some stem cell-like potential. The culture conditions we
applied in this study are unlikely to be optimal for cancer stem-like
cells in MPNST. This may also be reflected in the difficulties in
establishing permanent cultures from fresh tumors, even in
standard culture conditions with serum [14].
Figure 6. Tumor formation in immunodeficient nude mice. (A) Frequency and time of tumor formation with 2.5610
5 adherent (n=10,
passage 35) or clonal sphere S462 (n=9), CD133
+ (n=9) and CD133
2 (n=5) cells injected subcutaneously. All sphere cells were obtained between
passages 8 and 13. Adherent versus spheres and adherent versus CD133+ spheres p,0.05 *. (B) Histology of tumors derived from adherent cells (left
panel) and sphere cells showed that these tumors resemble MPNSTs. H&E shows typical spindle shape cells of MPNST (arrows, top panel), which are
highly proliferative by Ki-67 immunstaining (arrows, middle panel) and negative for S100 (bottom panel). Bar=200 mm, applies for all the
micrographs. (C) Cells dissociated from mice tumors formed secondary spheres in vitro (representative secondary sphere 3 weeks after plating single
cells). Bar=20 mm.
doi:10.1371/journal.pone.0021099.g006
MPNST Cancer Stem Cells
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markers, including Nestin, NFGR CD133 and CD34 to varying
degrees, suggesting that these cells are less differentiated and more
immature. Expression of these markers was substantially increased
in clonal spheres supporting our hypothesis that stem-like cells are
enriched in the spheres. CD133+ S462 spheres had a higher
frequency of sphere formation in vitro and tumor formation in mice
when compared to CD1332 spheres. This marker thus marks
cancer stem-like cells in MPNST to some extent, but not
exclusively.
Neural crest stem cells have the ability to self-renew and
differentiate into a number of lineages including neurons, glia, and
myofibroblasts [15,16]. In the presence of respective growth
factors, cells of the MPNST S462 clonal spheres differentiated into
cells resembling Schwann cells, SM/Fb and neurons. Such lineage
differentiation was much less profound and less frequent in the
adherent MPNST cells. These findings suggest that undifferenti-
ated or dedifferentiated cells, which possess a higher potential for
differentiation than differentiated cells, are enriched in clonal S462
spheres. In fact, CD34, a glycophosphoprotein, normally ex-
pressed by mature endothelial cells, mesenchymal and hemato-
poetic progenitor cells, and more importantly in neural stem cells
is also localised in MPNSTs tumours, probably in endoneurial
fibroblasts [17,18]. The increase in expression of this marker in the
spheres indicates that an increasing number of cells is associated
with a more undifferentiated phenotype under the stem cell
conditions used. It is also possible that neural stem cell culture
conditions induce or promote dedifferentiation of S462 cells or
proliferation of stem-like cells present in the parental population.
Self-renewal is one of the properties of stem-like cells. The
increase in sphere formation with passaging in stem cell media
suggests that the frequency of stem-like cells within the spheres
increases with growth, as would be expected if these culture
conditions select for, or support increased proliferation, or
survival, of stem-like cells. Hence, an enrichment of cancer stem
cells in spheres together with reduced proportions of differentiated
cells is the likely cause for the increased tumorigenic potency of
spheres. Interestingly, as seen in native MPNST, mouse-derived
tumors showed indeed no expression of the Schwann cell
differentiation marker S100.
Our results provide evidence for the existence of cancer stem or
stem cell-like cells in MPNST. These cells grow as clonal spheres
for multiple passages under neural stem cell cultural conditions,
express stem/progenitor cell markers and induce tumor formation
in immunodeficient nude mice at a substantially higher frequency
than adherent cells. Studying these cells may contribute to a better
understanding of the biology and pathogenesis of MPNST and
may enable identification of specific targets for the development of
therapies.
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